ABSTRACT
The COVID-19 pandemic, a disease caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), emerged in 2019 and quickly spread worldwide. Genomic surveillance has become the gold standard methodology to monitor and study this emerging virus. The current deluge of SARS-CoV-2 genomic data being generated worldwide has put additional pressure on the urgent need for streamlined bioinformatics workflows for data analysis. Here, we describe a workflow developed by our group to process and analyze large-scale SARS-CoV-2 Illumina amplicon sequencing data. This workflow automates all the steps involved in SARS-CoV-2 genomic analysis: data processing, genome assembly, PANGO lineage assignment, mutation analysis and the screening of intrahost variants. The workflow presented here (https://github.com/dezordi/ViralFlow) is available through Docker or Singularity images, allowing implementation in laptops for small scale analyses or in high processing capacity servers or clusters. Moreover, the low requirements for memory and CPU cores makes it a versatile tool for SARS-CoV-2 genomic analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Council for Scientific and Technological Development by the productivity research fellowship level 2 for Wallau GL (303902/2019-1) and by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Aggeu Magalhaes Institute Ethical Committee - CAAE 32333120.4.0000.5190.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used a public dataset of 86 Brazilian SARS-CoV-2 Illumina paired-end libraries, generated by amplicon sequencing method using the Illumina COVIDSeq protocol, available under the EMBL-EBI study accession PRJEB47823. The code and workflow documentation is available on https://github.com/dezordi/ViralFlow. And the supplementary data is available on [https://doi.org/10.6084/m9.figshare.16695262.v1].
